Managing Weight Gain and Metabolic Issues in Patients Treated With Atypical Antipsychotics
J Clin Psychiatry 2008;69(2):e04
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
The proven efficacy of second-generation antipsychotics (SGA) has led many
clinicians to switch patients from a conventional antipsychotic to an SGA.
However, SGAs may be associated with weight gain, dyslipidemia, high blood
pressure, and ultimately with cardiovascular disease, diabetes, and metabolic
syndrome. Clinicians should be aware of patients’ individual risk factors for
developing these illnesses and should carefully screen for changes in weight,
body mass index, waist size, or lipid levels that could be potentially harmful
and increase the risk for a more serious illness.
See the entire activity.